FUVID Study: Functional Characterization of Children With Chronic Venous Thromboembolic Disease
Key facts
- Who runs it
- University of Texas Southwestern Medical Center
- Where
- Atlanta, Boston, Chicago, Cincinnati, Columbus, Dallas, Fort Worth, Houston, Kansas City, Little Rock, Mount Pleasant, Oklahoma City, Philadelphia, and St. Petersburg, United StatesSee the 14 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 115 people enrolled
- Started
- 22 Dec 2020
- Expected to end
- Mar 2027
- Type of study
- Observational, 2 groups
- Treatments tested
- Blood draw (Visit 1)
- Blood draw (Visits 2 and 3)
- Record updated
- 8 June 2026
Who can take part
- Age
- 8 years to 21 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Ages 8 to ≤ 21 years
- Participant must be able to speak and understand English
- Be willing to participate and able to comply with the study protocol
- For participants with PE: Children with acute, radiologically confirmed pulmonary embolism (PE) with our without DVT
- For control group: Cohort 1: Children who are prescribed physical activity restrictions for 2 up to 12 weeks following any minor outpatient surgery or, minor injury (surgery or injury is referred to as "diagnosis" hereafter) Cohort 2: Children who are not prescribed physical activity restrictions and are otherwise considered to be healthy
Who cannot take part
- Frequent severe exacerbations of asthma defined by two or more bursts of systemic glucocorticoids (more than three days each) in the previous year or at least one hospitalization, intensive care unit stay or mechanical ventilation in the previous year. Patients should also be excluded if there are daily symptoms of asthma requiring daily use of short-acting bronchodilators such as albuterol or levalbuterol administration. The use of controller medications such as daily inhaled corticosteroids for mild persistent asthma is not exclusionary
- Prior history of DVT or PE (upper extremity, cerebral sinus venous thrombosis and abdominal thromboses encountered as a neonate are not exclusion criteria)
- Congenital heart disease with abnormal pulmonary circulation or with in-situ pulmonary artery thrombosis
- Chronic kidney disease
- Chronic inflammatory or an autoimmune disorder (such as systemic lupus erythematosus, juvenile rheumatoid disorder, inflammatory bowel disease, and sickle cell disease)
- A metabolic or endocrinological disorder such as diabetes mellitus or thyroid disorder
- History of or active cancer
- Has any other medical condition, which in the opinion of the investigator may potentially compromise the safety or compliance of the patient or may preclude the patient's successful completion of the clinical study; Additional exclusion criteria for participants with PE:
- Pregnant
- Musculoskeletal limitations to exercise expected to be present uptil 4 months post-diagnosis
- Weight ≥ 300 lbs
- Contraindications to magnetic resonance imaging
- Lack of anticoagulant treatment for the acute VTE due to contraindications
Where in United States
- Emory University / Children's Heathcare AtlantaAtlanta, United States
- Boston Children's HospitalBoston, United States
- Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United States
- Cincinnati Childrens HospitalCincinnati, United States
- Nationwide Children's HospitalColumbus, United States
- UT Southwestern Medical Center / Children's Medical CenterDallas, United States
- Cook Childrens Medical CenterFort Worth, United States
- Texas Children's HospitalHouston, United States
- Childrens Mercy HospitalKansas City, United States
- Arkansas Childrens Research Institute (ACRI)Little Rock, United States
- Central Michigan UniversityMount Pleasant, United States
- University of Oklahoma Health Sciences CenterOklahoma City, United States
- Children's Hospital of PhiladelphiaPhiladelphia, United States
- Johns Hopkins All Childrens HospitalSt. Petersburg, United States
About the trial
What the trial wants to find out
This is a multi-center prospective cohort study of patients with first-episode deep venous thrombosis and pulmonary embolism.
The 2 groups in the trial
- Participants with Pulmonary Embolism
The target accrual is based on the primary endpoint (exercise intolerance and dyspnea on exertion). To achieve adequate power and precision in the primary analysis, the target enrollment is 80 children. Both males and females of all races and ethnic groups are eligible for this study.
Treatment: Blood draw (Visit 1) and Blood draw (Visits 2 and 3)
- Control Group
A positive control group that has not had pulmonary embolism (PE) but is prescribed physical activity restrictions expected to produce a similar deconditioning effect as patients with PE will be enrolled from UT Southwestern only (cohort 1) or children who are no prescribed physical activity restrictions and are otherwise considered healthy (cohort 2). The target accrual of the positive control group is based on feasibility and availability of funds and will be limited to 25 controls.
Treatment: Blood draw (Visits 2 and 3)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- FUVID Study: A Multi-center, Prospective Study Evaluating Exercise Intolerance and Dyspnea on Exertion in Patients Following First-episode Deep Venous Thrombosis and Pulmonary Embolism
- Record updated
- 8 June 2026